 "An Abbott company logo is pictured at the reception of its office in Mumbai")
Abbott India outperformed the Indian pharmaceutical market (IPM) with a year-on-year (YoY) growth of 23 per cent in February. The domestic market grew at a robust 20 per cent on a low base, primarily led by volume growth and price hikes.
Abbott continued to outperform the sector in the anti-diabetic space with a growth of 20 per cent and key brands such as Thyronorm (hypothyroidism), biliary agent Udiliv, insulin Ryzodeg posted robust growth.
Sharekhan Research points out that Abbott India’s sales clocking above the IPM growth over the last several months indicates resilience of the company’s key brands across its
